May 2025 – Page 8

Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed

3 months ago talkbio0Tagged Americas, Biopharma, CEO, Chris Boerner, dealmaking, global competitiveness, Growth, innovation, Myers, squibb

Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio

Sanofi Announces $20 Billion US Investment Over Five Years

3 months ago talkbio0Tagged Big Pharma, development aspects, domestic partnerships, Drug Industry, Investments, Manufacturing, research, sanofi, Surgical construction, tariffs, U.S.

Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships

Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus

3 months ago talkbio0Tagged Autoimmune Diseases, CAR-T, KYV-101, Kyverna, layoffs, pipeline development, Staff

Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

3 months ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger

Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Biological Markers, Boehringer Ingelheim, Cancer Research, Discover, Drug Development, Neoplasms, real-world data, strategic collaboration, Tempus AI

Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration

Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs

3 months ago talkbio0Tagged cardiometabolic diseases, Collaboration, Diabetes Mellitus, Non-Insulin-Dependent, G-Protein-Coupled Receptors, Gastric Inhibitory Polypeptide, Glucagon Receptor, Glucagon-Like Peptide 1, Nordisk, Obesity, oral drugs, Septerna, small molecule therapies

Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals

Sanofi Commits $20 Billion to US Expansion Amid Industry-Wide Investment Surge

3 months ago talkbio0Tagged drug production, Industry, Investments, pharmaceutical manufacturing, R&D, sanofi, supply chain, Surgical construction, trends qualifier, U.S.

Sanofi; US investment; pharmaceutical manufacturing; R&D; drug production; job creation; supply chain; industry trends

Bayer Restructuring Cuts 2,000 Jobs, Thins Management Layers in 2025

3 months ago talkbio0Tagged Bayer, Drug Industry, Frankfurt plant closure, layoffs, management layers, restructuring

Bayer; restructuring; job cuts; management layers; layoffs; Frankfurt plant closure; pharmaceutical industry

Arcturus Prunes Early-Stage Pipeline to Focus on mRNA Therapies

3 months ago talkbio0Tagged Arcturus, biotech strategy, cash runway, Cystic Fibrosis, Kostaive, mRNA therapies, Ornithine carbamoyltransferase deficiency, pipeline reduction, vaccine programs

Arcturus Therapeutics; pipeline reduction; mRNA therapies; cystic fibrosis; ornithine transcarbamylase deficiency; Kostaive; vaccine programs; biotech strategy; cash runway

GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena

3 months ago talkbio0Tagged Analog, Boston Pharmaceuticals, drug acquisition, efimosfermin alfa, fibroblast growth factor 21, Liver diseases, MASH, Phase III, SLC17A5 gene, SmithKline Beecham

GSK; Boston Pharmaceuticals; efimosfermin alfa; Phase III; liver disease; MASH; SLD; drug acquisition; FGF21 analog